Literature DB >> 19620509

Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function.

Suetonia C Palmer1, Timothy C R Prickett, Eric A Espiner, Timothy G Yandle, A Mark Richards.   

Abstract

Production and clearance of plasma C-type natriuretic peptide (CNP) and amino terminal (NT)-proCNP immunoreactivity in the human circulation remain poorly characterized. Accordingly, we have measured arterial and venous concentrations of CNP and NT-proCNP across multiple tissue beds during cardiac catheterization in 120 subjects (age: 64.2+/-9.0 years; 73% men) investigated for cardiovascular disorders. The heart, head and neck, and musculoskeletal tissues made the clearest contributions to both plasma CNP and NT-proCNP (P<0.05). Net release of NT-proCNP was also observed from hepatic tissue (P<0.001). Negative arteriovenous gradients for CNP were observed across renal, hepatic, and pulmonary tissue (P<0.05), indicating net clearance, whereas no tissue-specific site of NT-proCNP clearance was identified. Age, mean pulmonary artery pressure, left ventricular end diastolic pressure, Brandt score of myocardial jeopardy, and troponin I were independent predictors of circulating CNP levels in multivariable analysis. Sex and kidney function were independently predictive of arterial NT-proCNP. The proportional step-up of CNP (+60%) across the heart was less than for brain natriuretic peptide (+123%) but greater than for NT-pro-brain natriuretic peptide (NT-proBNP) (+36%) and NT-proCNP (+42%; P<0.001 for all). We conclude that cardiac and head and neck tissue are important sources of CNP. Circulating CNP but not NT-proCNP concentrations are related to cardiac hemodynamic load and ischemic burden. Although cardiac release is most evident, multiple additional tissues release NT-proCNP immunoreactivity without evidence for an organ-specific site for NT-proCNP degradation. Taken together, differences in magnitude and direction of transorgan gradients for CNP compared with NT-proCNP suggest net generalized cosecretion with differing mechanisms of clearance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620509     DOI: 10.1161/HYPERTENSIONAHA.109.135608

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

1.  The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide.

Authors:  S Jeson Sangaralingham; Brenda K Huntley; Fernando L Martin; Paul M McKie; Diego Bellavia; Tomoko Ichiki; Gerald E Harders; Horng H Chen; John C Burnett
Journal:  Hypertension       Date:  2010-12-28       Impact factor: 10.190

2.  Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.

Authors:  Tomoko Ichiki; John A Schirger; Brenda K Huntley; Frank V Brozovich; Joseph J Maleszewski; Sharon M Sandberg; S Jeson Sangaralingham; Soon J Park; John C Burnett
Journal:  J Mol Cell Cardiol       Date:  2014-08-09       Impact factor: 5.000

3.  Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) predicts height velocity in healthy children.

Authors:  Robert C Olney; Joseph W Permuy; Timothy C R Prickett; Joan C Han; Eric A Espiner
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

4.  Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.

Authors:  S Jeson Sangaralingham; Paul M McKie; Tomoko Ichiki; Christopher G Scott; Denise M Heublein; Horng H Chen; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

Review 5.  Novel vasodilators in heart failure.

Authors:  Payman Zamani; Barry H Greenberg
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 6.  Natriuretic peptide metabolism, clearance and degradation.

Authors:  Lincoln R Potter
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

Review 7.  Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling.

Authors:  Rosita Zakeri; John C Burnett; S Jeson Sangaralingham
Journal:  Clin Chim Acta       Date:  2014-12-12       Impact factor: 3.786

8.  Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats.

Authors:  Peng Hu; Jing Wang; Xue Qi Zhao; Bo Hu; Ling Lu; Yuan Han Qin
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

9.  Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis.

Authors:  Tomoko Ichiki; Guido Boerrigter; Brenda K Huntley; S Jeson Sangaralingham; Paul M McKie; Gail J Harty; Gerald E Harders; John C Burnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

Review 10.  C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target.

Authors:  Natalie G Lumsden; Rayomand S Khambata; Adrian J Hobbs
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.